27Feb 2025
GLP-1 RAs Lower Mortality and CV Risks in Diabetic Kidney Transplant Recipients

GLP-1 RAs Lower Mortality and CV Risks in Diabetic Kidney Transplant Recipients

A retrospective cohort study of 35,488 kidney transplant recipients (KTRs) with type 2 diabetes found that GLP-1 receptor agonist (RA) use within 3 months post-transplant significantly reduced mortality (aHR 0.39), major adverse cardiovascular events (aHR 0.66), and major adverse kidney events (aHR 0.66). Despite benefits, GLP-1 RAs remain underutilized in this high-risk group.

  • #nephrology
  • #cardiology

Like

Save

Share